
Sign up to save your podcasts
Or
Sequel is combining the experience of its four co-founders to develop the next generation of insulin pumps, aiming to provide better delivery capabilities, CEO Alan Lotvin tells Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Lotvin sits down with BI analyst Matt Henriksson for an in-depth interview on the path insulin pumps have taken over the past 50 years to close in on a truly automated delivery system. They also discuss Sequel’s development of its twiist delivery system, designed to better titrate insulin injected into the body, and its strategy for commercial launch in 2025.
See omnystudio.com/listener for privacy information.
5
22 ratings
Sequel is combining the experience of its four co-founders to develop the next generation of insulin pumps, aiming to provide better delivery capabilities, CEO Alan Lotvin tells Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Lotvin sits down with BI analyst Matt Henriksson for an in-depth interview on the path insulin pumps have taken over the past 50 years to close in on a truly automated delivery system. They also discuss Sequel’s development of its twiist delivery system, designed to better titrate insulin injected into the body, and its strategy for commercial launch in 2025.
See omnystudio.com/listener for privacy information.
1,199 Listeners
2,174 Listeners
1,784 Listeners
394 Listeners
122 Listeners
771 Listeners
91 Listeners
9,189 Listeners
147 Listeners
246 Listeners
15,237 Listeners
351 Listeners
17 Listeners
461 Listeners
371 Listeners